Aller au contenu principal
Profil bibliographique

Allen Xue

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

64Publications signalées
6760Citations signalées
1Affiliations récentes

Les institutions déclarées

Les domaines associés

CAR-T cell therapy researchLipoproteins and Cardiovascular HealthBiosimilars and Bioanalytical MethodsLymphoma Diagnosis and TreatmentPharmaceutical Economics and Policy

Les publications récentes

Accès ouvert 2026 article OpenAlex

Comparative pharmacokinetic derivations for axicabtagene ciloleucel and brexucabtagene autoleucel in the treatment of B cell malignancies

Shruti Sanjay Salunkhe, Jenny Nater, Colleen Schweitzer, Daqin Mao et autres

Axicabtagene ciloleucel (axi-cel) and brexucabtagene autoleucel (brexu-cel) are autologous anti-CD19 chimeric antigen receptor (CAR) T cell products originally approved in the pivotal ZUMA-1 and ZUMA-2 clinical studies for the treatment of relapsed/refractory (r/r) large B cell lymphoma (r/r LBCL) and r/r mantle …

au (code pays fourni par la source)

2 citations Molecular Therapy Advances
2025 article OpenAlex

A Weighted Geometric Average Hazard Ratio Based Sample Size Formula for Non‐Proportional Hazards and Its Application to a Smoothed Piecewise Model in Cancer Immunotherapy Trial Design

Qingyang Zhang, Zixing Wang, Allen Xue, James B. Whitmore

Cancer immunotherapy trials often present unique challenges for time-to-event data modeling and analysis due to heterogeneous treatment effects across time or subgroups. A few known scenarios are delayed treatment effects and cure rates, where survival and hazard functions often take complex shapes. …

0 citations Pharmaceutical Statistics
Accès ouvert 2025 article OpenAlex

Evaluation of Lumbar Stabilizing Muscles in Dynamic Sagittal Imbalance Based on Surface Electromyography

Allen Xue, Hao Liu, Zhen Wang, Gaojian Tao et autres

Study DesignCase-control Study.ObjectiveTo evaluate the alterations in lumbar stabilizing muscles, particularly the erector spinae (ES), lumbar multifidus (LM), and gluteus maximus (Gmax), and their association with dynamic sagittal imbalance (DSI) after ambulation.MethodsThis study included patients with low back pain and anterior trunk …

cn (code pays fourni par la source)

1 citation Global Spine Journal
Accès ouvert 2025 article OpenAlex

Structure of the microtubule-anchoring factor NEDD1 bound to the γ-tubulin ring complex

Hugo Muñoz-Hernández, Yixin Xu, Aitor Pellicer Camardiel, Daniel X. Zhang et autres

The γ-tubulin ring complex (γ-TuRC) is an essential multiprotein assembly that provides a template for microtubule nucleation. The γ-TuRC is recruited to microtubule-organizing centers (MTOCs) by the evolutionarily conserved attachment factor NEDD1. However, the structural basis of the NEDD1-γ-TuRC interaction is not …

ch, ru, us (code pays fourni par la source)

9 citations The Journal of Cell Biology
Accès ouvert 2024 preprint OpenAlex

Structure of the microtubule anchoring factor NEDD1 bound to the γ-tubulin ring complex

Hugo Muñoz-Hernández, Yixin Xu, Daniel Y. Zhang, Allen Xue et autres

Summary The γ-tubulin ring complex (γ-TuRC) is an essential multiprotein assembly, in which γ-tubulin, GCP2-6, actin, MZT1 and MZT2 form an asymmetric cone-shaped structure that provides a template for microtubule nucleation. The γ-TuRC is recruited to microtubule organizing centers (MTOCs), such as …

ch, us (code pays fourni par la source)

3 citations bioRxiv (Cold Spring Harbor Laboratory)
2024 other OpenAlex

[Analysis of the accuracy between orthopedic robot-assisted and traditional manual pedicle screw placement techniques in adult degenerative scoliosis posterior surgery].

S. J. Zhao, Allen Xue, Yi Li, Jingyu Chen et autres

It suggests that robot-assisted pedicle screw placement in posterior surgery for patients with ADS can significantly improve the accuracy of screw placement and reduce the incidence of facet joint violation.

cn, us (code pays fourni par la source)

1 citation PubMed
2023 article OpenAlex

Sample size calculation for mixture model based on geometric average hazard ratio and its applications to nonproportional hazard

Zixing Wang, Qingyang Zhang, Allen Xue, James B. Whitmore

With the advent of cancer immunotherapy, some special features including delayed treatment effect, cure rate, diminishing treatment effect and crossing survival are often observed in survival analysis. They violate the proportional hazard model assumption and pose a unique challenge for the conventional …

us (code pays fourni par la source)

3 citations Pharmaceutical Statistics
Accès ouvert 2023 preprint OpenAlex

Structure of the γ-tubulin ring complex-capped microtubule

Amol Aher, L. Urnavicius, Allen Xue, Kasahun Neselu et autres

Microtubules are composed of α/β-tubulin dimers positioned head-to-tail to form protofilaments that associate laterally in varying numbers. It is not known how cellular microtubules assemble with the canonical 13-protofilament architecture, resulting in micrometer-scale α/β-tubulin tracks for intracellular transport that align with, rather …

us (code pays fourni par la source)

3 citations bioRxiv (Cold Spring Harbor Laboratory)
2023 conference-abstract OpenAlex

Statistical Challenges from Trials of Potentially Curative Treatments: Validation of Cure Assumptions When Analyzing Zuma-7 Follow-up Data of Axi-Cel and Standard of Care Therapy

Anik R. Patel, Mark Ray, Yael Rodríguez‐Guadarrama, Nathaniel Smith et autres

Introduction: ZUMA-7 is the largest randomized controlled trial (RCT) for chimeric antigen receptor (CAR) T-cell therapy which compared axicabtagene ciloleucel (Axi-cel) to standard of care (SoC) including autologous stem cell transplant (ASCT) for the treatment of relapsed or refractory DLBCL. Both arms …

2 citations Blood
2023 conference-abstract OpenAlex

Curative Potential of Axicabtagene Ciloleucel (Axi-Cel): An Exploratory Long-Term Survival Assessment in Patients with Refractory Large B-Cell Lymphoma from ZUMA-1

Sattva S. Neelapu, Caron A. Jacobson, Armin Ghobadi, David B. Miklos et autres

Background: Axi-cel is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL). Long-term results from ZUMA-1, a multicenter, single-arm, Phase 1/2 study of axi-cel in patients with refractory LBCL, demonstrated …

us (code pays fourni par la source)

5 citations Blood
Accès ouvert 2023 article OpenAlex

PB2319: ZUMA-23: A GLOBAL, PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD OF CARE AS FIRST-LINE THERAPY IN PATIENTS WITH HIGH-RISK LARGE B-CELL LYMPHOMA

Jason R. Westin, Caron A. Jacobson, Julio C. Chávez, Anna Sureda et autres

Topic: 19. Aggressive Non-Hodgkin lymphoma - Clinical Background: The nearly 40% of patients with large B-cell lymphoma (LBCL) who are refractory to or relapse after current first-line standard-of-care (SOC) regimens, such as R-CHOP (rituximab [R] + cyclophosphamide [C], doxorubicin [H], vincristine [O], …

us, es, fr, de, au, gb, nl (code pays fourni par la source)

7 citations HemaSphere

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.